Moderna Now Trades 61% Above Wall Street's Average Price Target. Should You Sell?

The key risk is not whether the melanoma result is encouraging; it is whether investors are extrapolating one combination-trial readout into a scalable, multi-indication platform. Personalized manufacturing, turnaround time, treatment-center capacity, and reimbursement could constrain eligible patients and revenue even after approval. That makes clinical success and commercial value separate underwriting questions.

Near term, a sharp rerating leaves MRNA exposed to profit-taking or a “sell the news” reaction as regulators review the filing path. The cited premium to analyst targets is a positioning warning, not a standalone valuation signal: targets may lag fast-moving data. Over 1–3 months, watch regulatory feedback, full trial data and safety, and any filing timeline. Over 6–18 months, manufacturing throughput and adoption evidence matter more than additional pipeline headlines.

Merck may benefit if Keytruda combination use extends its franchise, but the collaboration’s economics are not provided; do not translate MRNA’s upside directly into MRK earnings. The contrarian opportunity is that the market may underprice a genuine platform if results replicate beyond melanoma, while the bear case is that the market is overpricing efficacy before scalable delivery is demonstrated. No broad read-through to other mRNA developers is warranted from this trial alone.